Effects of probiotic treatment on patients and animals with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized control trials

IF 4.6 2区医学 Q2 IMMUNOLOGY

Frontiers in Cellular and Infection Microbiology Pub Date : 2024-09-11 DOI:10.3389/fcimb.2024.1411222

Ziying Su, Chenxi Ma, Xiaosong Ru, Sijia Zhang, Chuyi Wu, Yue Huang, Huijie Cen, Zihui Yin, Jianping Zhang

{"title":"Effects of probiotic treatment on patients and animals with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized control trials","authors":"Ziying Su, Chenxi Ma, Xiaosong Ru, Sijia Zhang, Chuyi Wu, Yue Huang, Huijie Cen, Zihui Yin, Jianping Zhang","doi":"10.3389/fcimb.2024.1411222","DOIUrl":null,"url":null,"abstract":"ObjectiveIn recent years, the lung-gut axis has received increasing attention. The oxidative stress and systemic hypoxia occurring in chronic obstructive pulmonary disease (COPD) are related to gut dysfunction. That suggests probiotics have a potential therapeutic role in COPD. In this study, we therefore evaluated the ameliorative effects of probiotics on COPD.MethodsSearches were conducted in four electronic databases, including PubMed, Cochrane Library, the NIH clinical registry Clinical Trials. Gov and EMBASE. The data extracted was analyzed statistically in this study using StataMP17 software, with mean difference (MD) chosen as the effect size for continuous variables, and the results expressed as effect sizes and their 95% confidence intervals (CIs). Standardized Mean Difference (SMD) was used if the data units were different.ResultsWe included three randomized, controlled, double-blind clinical trials and five randomized controlled animal studies. The results show that for lung function, probiotics improved %FEV1 in COPD patients (MD = 3.02, 95%CI: 1.10, 4.93). Additionally, in inflammation, probiotics increased IL-10 (SMD = 1.99, 95%CI: 1.02, 2.96) and decreased inflammatory markers such as TNF-α (SMD= -2.64, 95%Cl: -3.38, -1.90), IL-1β (SMD= -3.49, 95%Cl: -4.58, -2.40), and IL-6 (SMD= -6.54, 95%Cl: -8.36, -4.73) in COPD animals, while having no significant effect on C-reactive protein (MD = 0.30, 95%CI: -0.71, 1.32) in COPD patients. For lung structure, probiotics significantly reduced the degree of pulmonary collagen fibers deposition in COPD animals (SMD = -2.25, 95%CI: -3.08, -1.41).ConclusionOverall, probiotics may be an additional approach that can improve COPD. Further clinical trials are needed to evaluate the efficacy, safety, and impact factors of probiotics for COPD.Systematic Review Registrationhttps://inplasy.com/inplasy-2023-4-0023/, identifier INPLASY202340023.","PeriodicalId":12458,"journal":{"name":"Frontiers in Cellular and Infection Microbiology","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cellular and Infection Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcimb.2024.1411222","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

ObjectiveIn recent years, the lung-gut axis has received increasing attention. The oxidative stress and systemic hypoxia occurring in chronic obstructive pulmonary disease (COPD) are related to gut dysfunction. That suggests probiotics have a potential therapeutic role in COPD. In this study, we therefore evaluated the ameliorative effects of probiotics on COPD.MethodsSearches were conducted in four electronic databases, including PubMed, Cochrane Library, the NIH clinical registry Clinical Trials. Gov and EMBASE. The data extracted was analyzed statistically in this study using StataMP17 software, with mean difference (MD) chosen as the effect size for continuous variables, and the results expressed as effect sizes and their 95% confidence intervals (CIs). Standardized Mean Difference (SMD) was used if the data units were different.ResultsWe included three randomized, controlled, double-blind clinical trials and five randomized controlled animal studies. The results show that for lung function, probiotics improved %FEV1 in COPD patients (MD = 3.02, 95%CI: 1.10, 4.93). Additionally, in inflammation, probiotics increased IL-10 (SMD = 1.99, 95%CI: 1.02, 2.96) and decreased inflammatory markers such as TNF-α (SMD= -2.64, 95%Cl: -3.38, -1.90), IL-1β (SMD= -3.49, 95%Cl: -4.58, -2.40), and IL-6 (SMD= -6.54, 95%Cl: -8.36, -4.73) in COPD animals, while having no significant effect on C-reactive protein (MD = 0.30, 95%CI: -0.71, 1.32) in COPD patients. For lung structure, probiotics significantly reduced the degree of pulmonary collagen fibers deposition in COPD animals (SMD = -2.25, 95%CI: -3.08, -1.41).ConclusionOverall, probiotics may be an additional approach that can improve COPD. Further clinical trials are needed to evaluate the efficacy, safety, and impact factors of probiotics for COPD.Systematic Review Registrationhttps://inplasy.com/inplasy-2023-4-0023/, identifier INPLASY202340023.

查看原文本刊更多论文

益生菌治疗对慢性阻塞性肺病患者和动物的影响：随机对照试验的系统回顾和荟萃分析

近年来，肺-肠轴受到越来越多的关注。慢性阻塞性肺疾病（COPD）中出现的氧化应激和全身缺氧与肠道功能紊乱有关。这表明益生菌对慢性阻塞性肺病具有潜在的治疗作用。因此，在本研究中，我们评估了益生菌对慢性阻塞性肺病的改善作用。方法在四个电子数据库中进行了搜索，包括 PubMed、Cochrane Library、美国国立卫生研究院临床登记处 Clinical Trials.Gov 和 EMBASE。本研究使用 StataMP17 软件对提取的数据进行统计分析，对于连续变量，选择平均差（MD）作为效应大小，结果以效应大小及其 95% 置信区间（CI）表示。如果数据单位不同，则使用标准化均值差（SMD）。结果我们纳入了三项随机对照双盲临床试验和五项随机对照动物研究。结果显示，益生菌可改善慢性阻塞性肺病患者的肺功能（MD = 3.02，95%CI：1.10, 4.93）。此外，在炎症方面，益生菌增加了 IL-10（SMD=1.99，95%CI：1.02，2.96），降低了 TNF-α（SMD=-2.64，95%Cl：-3.38，-1.90）、IL-1β（SMD=-3.49，95%Cl：-4.58，-2.40）和 IL-6（SMD=-6.54，95%Cl：-8.36，-4.73），而对慢性阻塞性肺病患者的 C 反应蛋白（MD=0.30，95%CI：-0.71，1.32）无显著影响。在肺部结构方面，益生菌能显著降低慢性阻塞性肺病动物的肺胶原纤维沉积程度（SMD = -2.25，95%CI：-3.08，-1.41）。需要进一步的临床试验来评估益生菌对慢性阻塞性肺病的疗效、安全性和影响因素。系统综述注册https://inplasy.com/inplasy-2023-4-0023/，标识符为INPLASY202340023。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Cellular and Infection Microbiology IMMUNOLOGY-MICROBIOLOGY

CiteScore

7.90

自引率

7.00%

发文量

1817

审稿时长

14 weeks

期刊介绍： Frontiers in Cellular and Infection Microbiology is a leading specialty journal, publishing rigorously peer-reviewed research across all pathogenic microorganisms and their interaction with their hosts. Chief Editor Yousef Abu Kwaik, University of Louisville is supported by an outstanding Editorial Board of international experts. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Cellular and Infection Microbiology includes research on bacteria, fungi, parasites, viruses, endosymbionts, prions and all microbial pathogens as well as the microbiota and its effect on health and disease in various hosts. The research approaches include molecular microbiology, cellular microbiology, gene regulation, proteomics, signal transduction, pathogenic evolution, genomics, structural biology, and virulence factors as well as model hosts. Areas of research to counteract infectious agents by the host include the host innate and adaptive immune responses as well as metabolic restrictions to various pathogenic microorganisms, vaccine design and development against various pathogenic microorganisms, and the mechanisms of antibiotic resistance and its countermeasures.

文献相关原料

公司名称	产品信息	采购帮参考价格